efenamic Acid as Steroid-sparing Antiinflammatory Drug During Viral Phase of COVID-19: 5 Case Reports

Abstract

The diverse disease manifestations in coronavirus disease 2019 (COVID-19) patients are an enigma since some cases display
little to no symptoms, whereas others develop severe fever and pneumonia, leading to acute respiratory distress syndrome
and eventually death. Given the excessive inflammatory activity, there is a need to target a regulator of cellular inflammation
while leaving the antiviral pathways intact. Corticosteroids are used as potent anti-inflammatory agents; however, it may
also be linked with attenuation of viral clearance leading to nonuniform benefits across the disease spectrum. Mefenamic acid
can be used as a steroid-sparing, long-term drug in the management of COVID-19 and post-COVID inflammation. In this
article, the management of 5 mild-to-moderate COVID-19 cases using steroid-sparing anti-inflammatory agents is described.